{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.95 vs. cons $0.93",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue growth",
      "prediction": "BEAT",
      "answer": "pred ~4.0% vs. cons 3.5%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Reported revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$13.30B vs. cons $13.20B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 organic revenue growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~4.0%-5.0% vs. cons 4.5% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 comparable EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.24-$3.27 vs. cons $3.26 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 free cash flow",
      "prediction": "UNCHANGED",
      "answer": "guide ~$12.2B vs. cons $12.2B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Fairlife second-half revenue/profit impact",
      "prediction": "LOWER",
      "answer": "guide ~-$0.02 EPS vs. cons $0.00 EPS (2H2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.3,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.4,
  "day5_path": "FADE",
  "day5_rationale": "A ~2% EPS beat and organic-growth outperformance should initially support the shares, but unchanged FY2026 EPS guidance of roughly $3.24-$3.27 versus $3.26 consensus leaves limited upward out-period revision. Fairlife disruption and input-cost commentary imply ~$0.02 of second-half EPS pressure versus $0.00 in prior expectations, causing the initial gain to fade.",
  "day5_confidence": "MEDIUM"
}